切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2022, Vol. 16 ›› Issue (06) : 481 -486. doi: 10.3877/cma.j.issn.1674-0785.2022.06.004

临床研究

经鼻高流量氧气湿化治疗老年慢性阻塞性肺疾病急性加重合并呼吸衰竭的可行性研究
陈名珍1, 杨珺楠1,(), 李开来1, 赵旭静1, 薛安静1, 满姗姗1, 向平超2   
  1. 1. 100144 北京,北京大学首钢医院干部保健科
    2. 100144 北京,北京大学首钢医院呼吸与危重症医学科
  • 收稿日期:2021-12-03 出版日期:2022-06-15
  • 通信作者: 杨珺楠
  • 基金资助:
    北京大学首钢医院科研与发展基金资助课题(SGYYZ201612)

Feasibility of heated humidified high flow nasal cannula oxygen therapy for acute exacerbation of chronic obstructive pulmonary disease with respiratory failure in elderly patients

Mingzhen Chen1, Junnan Yang1,(), Kailai Li1, Xujing Zhao1, Anjing Xue1, Shanshan Man1, Pingchao Xiang2   

  1. 1. Department of Cadre's Ward, Peking University Shougang Hospital, Beijing 100144, China
    2. Department of Respiratory & Critical Care Medicine, Peking University Shougang Hospital, Beijing 100144, China
  • Received:2021-12-03 Published:2022-06-15
  • Corresponding author: Junnan Yang
引用本文:

陈名珍, 杨珺楠, 李开来, 赵旭静, 薛安静, 满姗姗, 向平超. 经鼻高流量氧气湿化治疗老年慢性阻塞性肺疾病急性加重合并呼吸衰竭的可行性研究[J]. 中华临床医师杂志(电子版), 2022, 16(06): 481-486.

Mingzhen Chen, Junnan Yang, Kailai Li, Xujing Zhao, Anjing Xue, Shanshan Man, Pingchao Xiang. Feasibility of heated humidified high flow nasal cannula oxygen therapy for acute exacerbation of chronic obstructive pulmonary disease with respiratory failure in elderly patients[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(06): 481-486.

目的

探讨经鼻高流量氧气湿化治疗(HFNC)老年慢性阻塞性肺疾病急性加重(AECOPD)合并呼吸衰竭的可行性。

方法

选择2016年12月至2022年1月在北京大学首钢医院住院的老年AECOPD合并呼吸衰竭患者176例,HFNC组82例,无创正压通气(NPPV)组94例。比较2组患者治疗后脉搏氧饱和度(SPO2)、动脉血二氧化碳分压(PaCO2)、氧合指数(OI)、呼吸频率(RR)、心率(HR)、平均动脉压(MAP)、舒适度评分、出院率、气管插管率、转重症监护室(ICU)率及死亡率。计量资料以

xˉ
±s表示,2组间比较采用独立样本t检验;计数资料以例数或百分比表示,采用χ2检验。

结果

HFNC组治疗30 min SPO2、1 h SPO2、6 h SPO2均显著高于NPPV组(t=-2.049、-2.618、-3.314,P=0.043、0.010、0.001);出院前SPO2显著低于NPPV组(t=2.162,P=0.033),但各时间点及出院前OI差异无统计学意义(P>0.05)。治疗6 h MAP HFNC组显著高于NPPV组(t=-2.209,P=0.029),但均在正常范围;治疗2天及3天HR HFNC组显著高于NPPV组(t=-2.199、-2.336,P=0.030、0.021);其余各时间点及出院前2组RR、HR、MAP均差异无统计学意义(P>0.05)。2组中PaCO2差异无统计学意义(P>0.05)。HFNC组舒适度评分显著高于NPPV组(t=-46.807,P<0.001)。2组患者出院率、转ICU率、气管插管率及死亡率比较差异均无统计学意义(P>0.05)。

结论

HFNC治疗老年AECOPD合并Ⅰ型或轻度Ⅱ型呼吸衰竭患者疗效与NPPV相当,HFNC较NPPV舒适度更高。

Objective

To investigate the feasibility of transnasal heated humidified high flow nasal cannula oxygen therapy (HFNC) in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure in elderly patients.

Methods

A total of 176 elderly patients with AECOPD complicated with respiratory failure who were hospitalized at Peking University Shougang Hospital from December 2016 to January 2022 were enrolled, including 82 patients in an HFNC group and 94 patients in an NPPV group. After treatment, pulse oxygen saturation (SPO2), arterial partial pressure of carbon dioxide (PaCO2), oxygenation index (OI), respiratory rate (RR), heart rate (HR), mean arterial pressure (MAP), comfort score, discharge rate, rate of endotracheal intubation, rate of transfer to intensive care unit (ICU), and mortality were compared between the two groups. The independent sample t-test was used for comparison between the two groups. Statistical data are expressed in percentage or number of cases and the χ2 test was used for their comparisons.

Results

The SPO2 values at 30 min, 1 h, and 6 h were significantly higher in the HFNC group than in the NPPV group (t=-2.049,-2.618, and -3.314, P=0.043, 0.010, and 0.001, respectively). SPO2 before discharge was significantly lower than that of the NPPV group (t=2.162, P=0.033), but OI at each time point and before discharge had no statistical significance (P>0.05). MAP at 6 h was significantly higher in the HFNC group than in the NPPV group (t=-2.209, P=0.029), but within the normal range. HRs at 2 h and 3 h in the HFNC group were significantly higher than those of the NPPV group (t=-2.199 and -2.336, P=0.030 and 0.021, respectively). There were no significant differences in RR, HR, or MAP between the two groups at other time points and before discharge (P>0.05). There was no significant difference in PaCO2 between the two groups (P>0.05). Comfort score in the HFNC group was significantly higher than that of the NPPV group (t=-46.807, P<0.001). There were no significant differences in discharge rate, ICU transfer rate, endotracheal intubation rate, and mortality between the two groups (P>0.05).

Conclusion

HFNC is as effective as NPPV in treating elderly patients with AECOPD complicated with type Ⅰ or mild type Ⅱ respiratory failure, and HFNC is more comfortable than NPPV.

表1 倾向得分匹配后HFNC组与NPPV组患者治疗前指标比较(
xˉ
±s
表2 2组治疗后指标比较(
xˉ
±s
项目

HFNC组

(82例)

NPPV组

(43例)

t P
治疗30 min
SPO2(%) 96.6±2.5 95.6±2.4 -2.049 0.043
RR(次/分) 21.2±3.1 20.6±2.4 -1.122 0.264
HR(次/分) 83.5±14.8 80.1±10.2 -1.337 0.184
MAP(mmHg) 89.3±10.1 89.6±7.9 0.191 0.849
治疗1 h
SPO2(%) 97.1±1.8 96.2±2.0 -2.618 0.010
RR(次/分) 20.9±3.5 20.5±2.4 -0.799 0.426
HR(次/分) 83.0±13.3 78.7±10.3 -1.830 0.070
MAP(mmHg) 88.4±8.6 89.7±11.1 0.683 0.496
治疗6 h
SPO2(%) 97.2±1.6 96.1±2.1 -3.314 0.001
RR(次/分) 20.4±3.9 20.6±2.8 0.264 0.792
HR(次/分) 83.0±13.6 78.6±13.9 -1.716 0.089
MAP(mmHg) 89.7±10.6 85.7±6.6 -2.209 0.029
治疗2天
SPO2(%) 92.6±10.4 94.0±2.9 1.128 0.262
PaCO2(mmHg) 49.1±9.0 47.1±9.3 -0.739 0.464
OI(mmHg) 248.3±59.5 219.2±32.4 -1.781 0.087
RR(次/分) 21.5±4.7 20.9±3.4 -0.791 0.430
HR(次/分) 84.3±17.8 77.4±13.7 -2.199 0.030
MAP(mmHg) 88.5±10.2 87.4±7.0 -0.595 0.553
治疗3天
SPO2(%) 93.3±9.1 94.4±2.5 0.993 0.323
PaCO2(mmHg) 47.0±9.3 45.7±7.7 -0.501 0.619
OI(mmHg) 204.0±51.3 229.4±40.8 1.483 0.150
RR(次/分) 20.7±4.5 20.5±2.7 -0.315 0.754
HR(次/分) 82.5±17.1 77.2±7.7 -2.336 0.021
MAP(mmHg) 87.8±8.6 86.8±6.7 -0.634 0.527
出院前
SPO2(%) 93.7±11.2 96.4±2.0 2.162 0.033
PaCO2(mmHg) 48.0±11.6 44.1±6.5 -1.916 0.059
OI(mmHg) 223.4±61.3 242.5±41.5 1.590 0.116
RR(次/分) 20.6±5.2 22.1±9.8 1.109 0.270
HR(次/分) 82.7±16.0 80.2±14.4 -0.844 0.400
MAP(mmHg) 87.5±8.6 87.7±7.2 0.123 0.902
舒适度评分(分) 4.9±0.1 1.8±0.3 -46.807 <0.001
表3 2组患者结局指标比较[例(%)]
1
王丽娟, 夏金根, 杨晓军. 成人经鼻高流量氧气湿化治疗的应用进展 [J]. 中华结核和呼吸杂志, 2016, 39(2): 153-157.
2
钟雪锋, 于鹏, 李燕明. 高流量湿化治疗模式用于伴呼吸节律异常的高龄患者困难撤机两例并文献复习 [J]. 中华老年医学杂志, 2018, 37(2): 167-170.
3
陈名珍, 杨珺楠, 李开来, 等. 经鼻高流量氧气湿化治疗改善老年患者呼吸衰竭的可行性研究 [J]. 中华老年医学杂志, 2020, 38 (10): 56-61.
4
叶青, 田瑞雪, 可爱华, 等. 经鼻高流量氧疗治疗老年重症肺炎的临床疗效和安全性研究 [J]. 中国医学装备, 2020, 17(2): 95-98.
5
刘会霞, 常亚潘, 杜娟. 经鼻高流量湿化氧疗在老年AECOPD合并心衰患者中的应用 [J]. 齐鲁护理杂志, 2021, 27(12): 142-144.
6
吴少珠, 周宇麒, 张苍, 等. 经鼻高流量湿化氧疗与无创正压通气对COPD急性加重合并呼吸衰竭患者的疗效及安全性比较 [J]. 新医学, 2019, 50(8): 593-597.
7
卢健聪, 邱惠中, 陈丽丽. 经鼻高流量氧疗对慢性阻塞性肺疾病急性加重合并呼吸衰竭患者治疗失败的危险因素分析 [J]. 检验医学与临床, 2021, 18(11): 1582-1586.
8
赵智东, 付会文, 崔利锋, 等. 经鼻高流量加温湿化吸氧治疗慢性阻塞性肺疾病急性加重合并呼吸衰竭的临床效果 [J]. 检验医学与临床, 2019, 16(15): 2196-2199.
9
中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版) [J]. 中华结核和呼吸杂志, 2013, 36(4): 255-264.
10
Parke RL, Eccleston ML, Mcguinness SP. The effects of flow on airway pressure during nasal high-flow oxygen therapy [J]. Respir Care, 2011, 56(8): 1151-1155.
11
Vargas F, Saint-Leger M, Boyer A, et al. Physiologic effects of high-flow nasal cannula oxygen in critical care subjects [J]. Respir Care, 2015, 60(10): 1369-1376.
12
Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure [J]. N Engl J Med, 2015, 372(23): 2185-2196.
13
Bräunlich J, Seyfarth HJ, Wirtz H. Nasal high-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report [J]. Multidiscip Respir Med, 2015, 10(1): 27.
14
中华医学会呼吸病学分会呼吸危重症医学学组, 中国医师协会呼吸医师分会危重症医学工作委员会. 成人经鼻高流量湿化氧疗临床规范应用专家共识 [J]. 中华结核和呼吸杂志, 2019, 42(2): 83-91.
15
Bräunlich J, Mauersberger F, Wirtz H. Effectiveness of nasal highflow in hypercapnic COPD patients is flow and leakage dependent [J]. BMC Pulm Med, 2018, 18(1): 14.
16
Storgaard LH, Hockey HU, Laursen BS, et al. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure [J]. Int J Chron Obstruct Pulmon Dis, 2018, 13: 1195-1205.
17
Weinreich UM. Domiciliary high-flow treatment in patients with COPD and chronic hypoxic failure: In whom can we reduce exacerbations and hospitalizations? [J]. PLoS One, 2019, 14(12): e0227221.
18
杨圣强, 张贵真, 刘贞, 等. 经鼻高流量治疗对慢性阻塞性肺疾病急性加重急性加重患者膈肌功能的影响: 一项前瞻性随机对照研究 [J]. 中华危重病急救医学, 2019, 31(5): 551-555.
19
Dysart K, Miller TL, Wolfson MR, et al. Research in high flow therapy: mechanisms of action [J]. Respir Med, 2009, 103(10): 1400-1405.
20
Pisani L, Betti S, Biglia C, et al. Effects of high-flow nasal cannula in patients with persistent hypercapnia after an acute COPD exacerbation: a prospective pilot study [J]. BMC Pulm Med, 2020, 20(1): 12.
21
Tan D, Walline JH, Ling B, et al. High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial [J]. Crit Care, 2020, 24(1): 489.
[1] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[2] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[3] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[4] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[5] 张海涛, 康婵娟, 翟静洁. 胰管支架置入治疗急性胆源性胰腺炎效果观察[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 654-657.
[6] 杨雪, 张伟, 尚培中, 宋创业, 尚丹丹, 张蔚. 胆囊十二指肠瘘结石经瘘口排出后自愈一例报道[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 707-708.
[7] 杨瑞洲, 李国栋, 吴向阳. 腹股沟疝术后感染的治疗方法探讨[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 715-719.
[8] 孔博, 张璟, 吕珂. 超声技术在复杂腹壁疝诊治中的作用[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 670-673.
[9] 姜明, 罗锐, 龙成超. 闭孔疝的诊断与治疗:10年73例患者诊疗经验总结[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 706-710.
[10] 邱朋, 邓正栋, 王剑明. 肝内胆管结石微创治疗策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 591-596.
[11] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[12] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[13] 卓徐鹏, 刘颖, 任菁菁. 感染性疾病与老年人低蛋白血症的相关性研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 896-899.
[14] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要